Smith KJ: Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals. Blood 721269,1988Smith, K., " Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals, " Blood, 72,1269-1277 (1988)....
A factor VIII variant has been characterized in which the heavy chain is directly fused to the light chain. Des-(741-1668)-factor VIII lacks the processing site at Arg1648, as Arg740 of the heavy chain is fused to Ser1669 of the light chain. The sequence of the fusion site is similar...
of therapeutic units. In 2019, the National Protocol for Diagnosis and Care in haemophilia recommended 2 methods for managing patients with haemophilia in the peri-operative period, either discontinuous injections of standard or extended half-life factor VIII/IX or a continuous infusion of FVIII/IX...
The apple domains of factor XIa have been implicated in several binding interactions with molecules involved in blood coagulation, including the calcium-dependent activation of factor IX (Baglia et al. 1991, Sun and Gailani 1996). Indeed, while isolated factor XIa catalytic domain can activate fact...
These results demonstrate that factor IX is not the thrombogenic component of some CC. Also, IX prepared by MAb immunoaffinity may have therapeutic advantage for patients at risk for thrombosis and adverse effects of contaminating proteins in commercial concentrates. 展开 ...
factor I, fibrinogen; factor II, prothrombin; factor III, thromboplastin; factor IV, calcium (ions); factor V, proaccelerin; factor VII, serum prothrombin conversion accelerator; factor VIII, antihemophilic factor; factor IX, plasma thromboplastin component; factor X, Stuart-Prower factor; factor ...
In the presence of hirudin, the initial activation of factors IX, X, and prothrombin was unchanged, however the further increment in prothrombin fragment F1 + 2 was markedly inhibited. These results demonstrate that factor XIa is a potential agonist of the intrinsic cascade in vivo, which ...
Factor IX (FIX) deficiency or dysfunction, or hemophilia B, is an X-linked inherited bleeding disorder, usually manifested in males and transmitted by females who carry the causative mutation on the X chromosome. Hemophilia B results from a variety of defects in the FIX gene. FIX deficiency is...
Emicizumab is a humanized bispecific antibody that binds to both activated coagulation factor IX and factor X, resulting in the generation of activated factor X.It is approved by the United States Food and Drug Administration for prophylaxis of bleeding in patients with congenital hemophilia A with...
A two-syringe collection technique was used: venipuncture was performed using a butterfly catheter (Surflo brand winged infusion set with a siliconized 19-gauge needle; Terumo Medical Corporation, Elkton, MD) through which 5-mL samples of blood were collected sequentially into two separate ...